According to a new market research report published by Global Market Estimates, the Global Viral Vector Manufacturing Market is projected to grow at a CAGR value of 20.5% from 2022 to 2027. The rising number of cancer patients affected by increased alcohol intake and unhealthy lifestyles, as well as the burgeoning utilization of viral vectors in novel therapeutic delivery, along with their use as effective carriers of virus-disabling sequence data and their convenience in delivering HIV-inhibiting transgenic organisms to human hematopoietic stem cells (HSCs), are all making a significant contribution to market expansion.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Viral Vector Manufacturing Market - Forecast to 2027" https://www.globalmarketestimates.com/market-report/viral-vector-manufacturing-market-3755

Key Market Insights

·         The adeno-associated viral vectors segment is expected to be the fastest-growing segment in the Viral Vector Manufacturing market from 2022 to 2027 as per the type outlook

·         The cancers segment is expected to be the fastest-growing segment in the Viral Vector Manufacturing market from 2022 to 2027 as per the disease outlook

·          Based on end-user, the pharmaceutical and biopharmaceutical companies segment is expected to be the fastest-growing segment in the Viral Vector Manufacturing market from 2022 to 2027

·         North America (the United States, Canada, and Mexico) will have a dominant share in the global Viral Vector Manufacturing market from 2022 to 2027

·         Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, uniQure, FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Johnson & Johnson (Janssen Global Services, LLC, Vibalogics, among others are key players in the viral vector manufacturing market.

Type Outlook (Revenue, USD Billion, 2022 - 2027)

·         Retroviral Vectors

·         Adenoviral Vectors

·         Adeno-associated Viral Vectors

·         Other Viral Vectors

Diseases Outlook (Revenue, USD Billion, 2022 - 2027)

·         Cancers

·         Genetic Disorders

·         Infectious diseases

·         Other Diseases

Application Outlook (Revenue, USD Billion, 2022 - 2027)

·         Gene Therapy

·         Vaccinology

End-User Outlook (Revenue, USD Billion, 2022 - 2027)

·         Pharmaceutical and Bio-pharmaceutical Companies

·         Research Institutes

Regional Outlook (Revenue, USD Billion, 2022-2027)

North America                                                                                 

• The U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC

Central & South America

• Brazil
• Argentina
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• UAE
• Rest of MEA

 

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +16026667238